Management of haemophilia in the developing world

被引:52
作者
Srivastava, A [1 ]
Chuansumrit, A
Chandy, M
Duraiswamy, G
Karagus, C
机构
[1] Christian Med Coll & Hosp, Dept Haematol, Vellore 632004, Tamil Nadu, India
[2] Univ Putra Malaysia, Fac Med & Hlth Sci, Serdang, Malaysia
[3] Red Cross War Mem Childrens Hosp, Dept Paediat, Rondebosch, South Africa
[4] Mahidol Univ, Ramathibodi Hosp, Dept Pediat, Bangkok 10700, Thailand
关键词
haemophilia; management; developing; world;
D O I
10.1046/j.1365-2516.1998.440474.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The problems with management of haemophilia in developing countries are poor awareness, inadequate diagnostic facilities and scarce factor concentrates for therapy. The priorities in establishing services for haemophilia include training care providers, setting up care centres, initiating a registry, educating affected people and their families about the condition, providing low-cost factor concentrates, improving social awareness and developing a comprehensive care team. A coagulation laboratory capable of reliably performing clotting times with correction studies using normal pooled, FVIII and FIX deficient patient plasma and factor assay is most essential for diagnosis. More advanced centralized laboratories are also needed. Molecular biology techniques for mutation detection and gene trading should be established in each country for accurate carrier detection and antenatal diagnosis. Different models of haemophilia care exist. In India, there is no support from the government. Services, including import of factor concentrates, are organized by the Haemophilia Federation of India, with support from other institutions. Haemophilia is managed with minimal replacement therapy (about 2000 i.u./PWH/year). In Malaysia, where the system is fully supported by the government, facilities are available at all public hospitals and moderate levels of factor concentrates are available 'on-demand' (about 11,000 i.u./PWH/year) at the hospitals. Haemophilia care in South Africa is provided through major public hospitals. Intermediate purity factor concentrates are locally produced (about 12,000 i.u./PWH/year) at low cost. The combined experience in the developing world in providing haemophilia services should be used to define standards for care and set achievable goals.
引用
收藏
页码:474 / 480
页数:7
相关论文
共 18 条
[1]   LOW-DOSE ACTIVATED FACTOR-IX COMPLEX CONCENTRATES (FEIBA(R)) FOR POSTOPERATIVE HEMOSTASIS IN A PATIENT WITH HIGH RESPONDING FACTOR-VIII INHIBITORS [J].
BHAVE, A ;
SRIVASTAVA, A ;
LEE, V ;
DANIEL, AJ ;
DENNISON, D ;
SUNDERAJ, GD ;
SUDARSANAM, A .
HAEMOPHILIA, 1995, 1 (04) :274-276
[2]  
Bhushan V., 1994, National Medical Journal of India, V7, P8
[3]   CHRISTMAS DISEASE - A CONDITION PREVIOUSLY MISTAKEN FOR HAEMOPHILIA [J].
BIGGS, R ;
DOUGLAS, AS ;
MACFARLANE, RG ;
DACIE, JV ;
PITNEY, WR ;
MERSKEY, C ;
OBRIEN, JR .
BRITISH MEDICAL JOURNAL, 1952, 2 (4799) :1378-1382
[4]   A COMPARISON OF THE ALLELIC FREQUENCIES OF 10 DNA POLYMORPHISMS ASSOCIATED WITH FACTOR-VIII AND FACTOR-IX GENES IN THAI AND WESTERN-EUROPEAN POPULATIONS [J].
GOODEVE, AC ;
CHUANSUMRIT, A ;
SASANAKUL, W ;
ISARANGKURA, P ;
PRESTON, FE ;
PEAKE, IR .
BLOOD COAGULATION & FIBRINOLYSIS, 1994, 5 (01) :29-35
[5]  
GOODEVE AC, IN PRESS BLOOD COAG
[6]  
GRAHAM JB, 1986, BLOOD, V67, P1554
[7]  
KARABUS CD, 1996, HAEMOPHILIA S1, V2, P18
[8]  
KARABUS CD, 1973, HOME TRANSFUSIONS HA
[9]   UNTITLED [J].
LEE, CA ;
BRETTLER, DB .
HAEMOPHILIA, 1995, 1 (01) :1-1
[10]   Prenatal diagnosis of haemophilia [J].
Ljung, RCR .
BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (02) :243-257